The BioBox

What The BioBox does

The BioBox, LLC is a privately held biotechnology company headquartered in Corona, California, founded in 2009 (with firmographic records also citing 2012). The company operates a cGMP-compliant manufacturing facility and a reference laboratory, and has spent approximately 15 years conducting research into the biology of cellular aging, with a focus on cell regeneration, rejuvenation, and repair using mesenchymal stem cell (MSC) science.

The company's commercial flagship product is UCM-X, a topical, organic, cell-derived secretome enriched with exosomes, collagen, elastin, and other bioactive proteins. The product is triple-filtered, characterized, and certified free of pathogenic viruses, and preclinical in-vitro studies have shown improved collagen and elastin concentrations in skin of 25- and 53-year-old users, with measured concentrations exceeding 580 ng/ml of hyaluronic acid and 28 ng/ml of elastin. Beyond the cosmetic UCM-X SKU, the company pursues a research pipeline covering natural killer (NK) cell-based immunotherapies, cell-based therapeutics for senescence, and IND-stage programs.

The BioBox monetizes UCM-X through a domestic distributor network targeting physicians, dermatologists, aestheticians, and their clients, supplemented by direct sales contact. Pricing is not publicly disclosed. The company holds patents (filed/pending) on stem cell technology for clinical applications and on cell-based therapeutics for senescence, and operates under cGMP, GTP for HCT/P, and GLP compliance regimes. It is a small organization with approximately 11 named team members spanning scientific R&D, regulatory/quality, and administrative functions, with no disclosed external funding or institutional investors.

Name

The BioBox

Legal name

The BioBox, LLC

Website

https://thebiobox.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

The BioBox is a privately held California biotech company that develops and sells UCM-X, a topical cell-derived secretome product enriched with exosomes, distributed through domestic distributors to physicians, dermatologists, aestheticians, and consumers for skincare applications.

Ownership category

akta.pro rank

Product category

Regenerative Skincare Biotechnology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Toilet Preparation Manufacturing (325620), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

akta.pro secondary industries

Acellular/Decellularized Matrices & ECM Products (HLAAAGAF), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Stem Cell–Based Regenerative Therapies (HLAAAGAA)

Keywords

• Cell-derived secretome products
• Exosome skincare technology
• Anti-aging biotechnology
• Regenerative medicine research
• Mesenchymal stem cell applications

Headquarters

HQ city

Corona

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. UCM-X Product Sales: Sale of topical cell-derived secretome product UCM-X to physicians, dermatologists, aestheticians, and consumers. Product is sold for cosmetic topical use as a skincare/anti-aging treatment.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

The BioBox develops, manufactures, and sells UCM-X, a topical, organic, cell-derived secretome product naturally enriched with exosomes, collagen, elastin, and other essential proteins derived from mesenchymal stem cells. UCM-X is positioned as a noninvasive skincare/anti-aging treatment used alongside cosmetic products or to enhance aesthetic procedures such as facials, microneedling, dermabrasion, and laser therapy, sold to physicians, dermatologists, aestheticians, and consumers.

Product overview

TheBioBox is a biotechnology company dedicated to improving health and wellness through research and development of cell-based products and a reference laboratory. For 15 years, scientists have been researching the biology of cellular aging with a focus on cell regeneration, rejuvenation, and repair. The company's main commercial product is UCM-X, a next-generation topical secretome/exosome product for skincare applications, targeting physicians, dermatologists, aestheticians, and their clients.

Differentiator

Problem solved

Functional benefit

Brands

• UCM-X: A topical, organic, cell-derived secretome product naturally enriched with exosomes, collagen, elastin, and other essential proteins designed to improve skin appearance by reducing acne scars, sunspots, fine lines, and wrinkles.

Products and services

• UCM-X A topical, organic, cell-derived secretome product naturally enriched with exosomes, collagen, elastin, and other essential proteins. Designed to improve the appearance of dull, damaged, and uneven skin by reducing acne scars, sunspots, fine lines, and wrinkles, and to help skin appear more radiant. Intended for use with skincare/cosmetic products or as a noninvasive addition to aesthetic procedures such as facials, microneedling, dermabrasion, and laser therapy. Manufactured in the U.S. under cGMP.

Quantifiable outcome

• Preclinical studies demonstrated significant improvement in collagen and elastin concentrations in skin of 25- and 53-year-old UCM-X users
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators2 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Kimera Labs: Kimera Labs develops exosome-based regenerative skincare products distributed through medical and aesthetic professionals. Directly comparable to TheBioBox in technology (MSC-derived exosomes/secretome), product category (topical regenerative skincare), and go-to-market (physicians/aestheticians).
• BENEV Company: BENEV is an established exosome and growth-factor skincare brand sold exclusively through physicians, med-spas, and licensed skincare professionals. Closely comparable in distribution model and product positioning to UCM-X.
• ExoCoBio: ExoCoBio is a global exosome-focused biotechnology company commercializing stem-cell-derived exosome cosmetics and skincare through professional channels. Comparable in core technology (exosome cosmeceuticals) and aesthetic-medicine channel.

Emerging players

• Elevai Labs: Elevai Labs develops exosome-based skincare serums targeted at medical aesthetic practices and providers. Comparable technology platform (stem-cell-derived exosomes for topical skin rejuvenation) with a similar early-stage commercial profile.
• Pluristem Therapeutics: Pluristem develops placenta-derived cell therapy products for regenerative indications including wound healing. Comparable in cell-based regenerative platform and cGMP biomanufacturing, though at clinical-stage scale.
• AgeX Therapeutics: AgeX is a biotechnology company focused on cellular aging and regenerative medicine, including stem-cell-derived therapeutics targeting age-related decline. Directly comparable research focus (biology of cellular aging) and technology base to TheBioBox's underlying R&D.

Broad incumbents

• Organogenesis: Organogenesis is a publicly-traded regenerative medicine company producing living-cell and skin-substitute therapies for wound healing and surgical applications. Overlaps with TheBioBox in regenerative skin biology and cGMP cell-based manufacturing, though at much larger scale and with FDA-approved products.
• Vericel Corporation: Vericel develops autologous cell therapies for sports medicine and severe burn treatment using cultured cell-based products. Comparable in cell-therapy manufacturing, cGMP operations, and regenerative-medicine commercial pathways.
• SkinCeuticals: SkinCeuticals is an established physician-channel skincare brand owned by L'Oréal, positioned in the 'medical-grade' skincare segment that TheBioBox's UCM-X also targets. Comparable in distribution (dermatologists, plastic surgeons, medical spas) rather than technology.
• SkinMedica (Allergan Aesthetics): SkinMedica is a major physician-dispensed skincare brand under Allergan Aesthetics, with growth-factor and anti-aging product lines targeting the same dermatology/aesthetic practice channel as UCM-X.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/the_biobox
• Facebookfacebook.com/thebiobox
• LinkedInlinkedin.com/company/the-biobox-llc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The BioBox